Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been given an average rating of “Buy” by the fifteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.50.
Several analysts have recently weighed in on VYGR shares. Canaccord Genuity set a $35.00 price objective on shares of Voyager Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 29th. Wedbush lowered shares of Voyager Therapeutics from an “outperform” rating to a “neutral” rating and set a $29.00 price objective for the company. in a research note on Monday, March 12th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Friday, March 16th. HC Wainwright assumed coverage on shares of Voyager Therapeutics in a research note on Monday, June 4th. They set a “buy” rating and a $30.00 price target for the company. Finally, Piper Jaffray Companies restated a “buy” rating and set a $40.00 price target on shares of Voyager Therapeutics in a research note on Monday, March 12th.
Shares of NASDAQ:VYGR traded up $0.26 during mid-day trading on Tuesday, hitting $19.36. The company had a trading volume of 10,452 shares, compared to its average volume of 663,576. The firm has a market capitalization of $631.55 million, a P/E ratio of -7.33 and a beta of 3.01. Voyager Therapeutics has a one year low of $8.10 and a one year high of $31.91.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.52). The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.00 million. Voyager Therapeutics had a negative net margin of 768.99% and a negative return on equity of 69.92%. equities research analysts anticipate that Voyager Therapeutics will post -2.59 EPS for the current fiscal year.
In other Voyager Therapeutics news, insider Bernard Ravina sold 2,451 shares of the business’s stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $18.38, for a total transaction of $45,049.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 33.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in VYGR. BB Biotech AG boosted its holdings in Voyager Therapeutics by 29.4% during the 1st quarter. BB Biotech AG now owns 1,992,641 shares of the company’s stock worth $37,442,000 after acquiring an additional 453,121 shares during the last quarter. BlackRock Inc. boosted its holdings in Voyager Therapeutics by 18.8% during the 1st quarter. BlackRock Inc. now owns 1,438,029 shares of the company’s stock worth $27,020,000 after acquiring an additional 227,266 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Voyager Therapeutics by 35.9% during the 1st quarter. Farallon Capital Management LLC now owns 890,000 shares of the company’s stock worth $16,723,000 after acquiring an additional 235,188 shares during the last quarter. Millennium Management LLC boosted its holdings in Voyager Therapeutics by 124.0% during the 1st quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after acquiring an additional 342,148 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Voyager Therapeutics by 19.2% during the 4th quarter. Wells Fargo & Company MN now owns 449,525 shares of the company’s stock worth $7,462,000 after acquiring an additional 72,335 shares during the last quarter. Institutional investors and hedge funds own 83.62% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.